It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glaucoma affects approximately 80 million individuals worldwide, a condition for which current treatment options are inadequate. The primary risk factor for glaucoma is elevated intraocular pressure. Intraocular pressure is determined by the balance between the secretion and outflow of aqueous humor. Here we show that using the RNA interference tool CasRx based on shH10 adenovirus-associated virus can reduce the expression of the aqueous humor circulation related genes Rock1 and Rock2, as well as aquaporin 1 and β2 adrenergic receptor in female mice. This significantly reduced intraocular pressure in female mice and provided protection to the retina ganglion cells, ultimately delaying disease progression. In addition, we elucidated the mechanisms by which the knockdown of Rock1 and Rock2, or aquaporin 1 and β2 adrenergic receptor in female mice, reduces the intraocular pressure and secures the retina ganglion cells by single-cell sequencing.
The primary risk factor for glaucoma is elevated intraocular pressure. Here, the authors show that AAV-delivered CasRx to reduce the expression of Rock1 and Rock2 as well as Aqp1 and Adrb2 can significantly reduce intraocular pressure, ultimately delaying glaucoma progression in mice.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Chinese Academy of Medical Sciences, Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University; NHC Key laboratory of Myopia and Related Eye Diseases; Key Laboratory of Myopia and Related Eye Diseases, Shanghai, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Shanghai Research Center of Ophthalmology and Optometry, Shanghai, China (GRID:grid.411079.a) (ISNI:0000 0004 1757 8722)
2 Chinese Academy of Medical Sciences, Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University; NHC Key laboratory of Myopia and Related Eye Diseases; Key Laboratory of Myopia and Related Eye Diseases, Shanghai, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Wenzhou Medical University, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou, China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990)
3 Wenzhou Medical University, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou, China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990)
4 Chinese Academy of Medical Sciences, Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University; NHC Key laboratory of Myopia and Related Eye Diseases; Key Laboratory of Myopia and Related Eye Diseases, Shanghai, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Queen Victoria Hospital, Corneo Plastic Unit & Eye Bank, East Grinstead, UK (GRID:grid.439490.3) (ISNI:0000 0004 0400 3188)